However, there is evidence that many patients whose tumor cells express high levels of PD-L1 exhibit poor response, while others with low or undetectable levels of PD-L1 show objective responses to ICBs, limiting its use in routine clinical practice [7,8]. Here, CD274 is linked to neoplasm.